Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children

Pediatric Infectious Disease Journal

Volumn 22, Issue 1, 2003, Pages 62-69

  Hainaut, Marc ^a   Ducarme, Martine ^b   Schandené, Liliane ^b   Peltier, Cécile Alexandra ^a   Marissens, Denise ^c   Zissis, Georges ^c   Mascart, Françoise ^b   Levy, Jack ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b ERASME HOSPITAL   (Belgium)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Age; CD4; CD8; Highly active antiretroviral therapy; Human immunodeficiency virus type 1 infected children; Immune reconstitution

Indexed keywords

ANTIRETROVIRUS AGENT; MITOGENIC AGENT; T LYMPHOCYTE RECEPTOR;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MALE; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION;

ADOLESCENT; AGE FACTORS; ANTIGENS, CD19; ANTIGENS, CD45; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDA ALBICANS; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MITOGENS; RECEPTORS, ANTIGEN, T-CELL; TETANUS TOXOID; TIME FACTORS;

EID: 0037233960     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200301000-00016     Document Type: Article

References (29)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA 2000;284:190-7.
3. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-16.
4. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
5. Sleasman JW, Nelson RP, Goodenow MM, et al. Immunore-constitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocytes lineages. J Pediatr 1999;134:597-606.
6. Gibb DM, Newberry A, Klein N, de Rossi A, Grosh-Woerner I, Babiker A, Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet 2000;355:1331-2.
7. Vigano A, Vella S, Saresella M, et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS 2000;14:251-61.
8. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000;14:2635-42.
9. + T cells and T cell activation markers in HIV-1 infected children on HAART. Clin Exp Immunol 2001;125:266-73.
10. van Rossum AMC, Scherpbier HJ, van Lochem EG, et al. Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS 2001;15:2267-75.
11. Douek DC, Koup RA, McFarland RD, Sullivan JL, Luzuriaga K. Effect of HIV on thymic function before and after antiretroviral therapy in children. J Infect Dis 2000;181:1479-82.
12. Scott-Algara D, Aboulker JP, Durier C, et al. CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART. Clin Exp Immunol 2001;126:295-303.
13. Borkowsky W, Stanley K, Douglas SD, et al. Immunologic response to combination nucleoside analogue plus protease inhibitor therapy in stable antiretroviral therapy-experienced human immunodeficiency virus-infected children. J Infect Dis 2000;182:96-103.
14. Chougnet C, Fowke KR, Mueller BU, et al. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. AIDS 1998;12:2397-406.
15. Essajee SM, Kim M, Gonzalez C, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS 1999;13:2523-32.
16. Chouguet C, Jankelevich S, Fowke K, et al. Long-term protease inhibitor-containing therapy results in limited improvement in T cell function but not restoration of interleukin-12 production in pediatric patients with AIDS. J Infect Dis 2001;184:201-5.
17. Hulstaert F, Hannet I, Deneys V, et al. Age-related changes in human blood lymphocyte subpopulations: II. Varying kinetics of percentage and absolute counts measurements. Clin Immunol Immunopathol 1994;70:152-8.
18. Centers for Disease Control and Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994;43:1-12.
19. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 1997;3:533-40.
20. + repertoire during antiviral therapy. Nat Med 1998;4:215-21.
21. + T cell receptor repertoire. J Infect Dis 1998;177:579-85.
22. Halapi E, Gigliotti D, Hodara V, et al. Detection of CD8 T-cell expansions with restricted T-cell receptor V gene usage in infants vertically infected by HIV-1. AIDS 1996;10:1621-6.
23. + T cells in HIV type 1 infection. AIDS Res Hum Retroviruses 1999;15:265-72.
24. Ogg GS, Jin X, Bonhoeffer S, et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999;73:797-800.
25. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70-9.
26. + T-cell activation in HIV infection is antigenic stimulation. J Acquir Immune Defic Syndr 2000;25:203-11.
27. + T-cell expansions in patients with human immunodeficiency virus infection receiving highly active combination therapy. Blood 2001;97:1787-95.
28. Hofmann B, Jakobsen KD, Odum N, et al. Relatively preserved phytohemagglutinin as opposed to decreased pokeweed mitogen responses may be due to possibly preserved responses via CD2/phytohemagglutinin pathway. J Immunol 1989;142:1874-80.
29. Clerici M, Roilides E, Butler KM, et al. Changes in T-helper cell function in human immunodeficiency virus-infected children during didanosine therapy as a measure of antiretroviral activity. Blood 1992;80:2196-202.